Alan Kohler from 'The Constant Investor' covers Patrys, page-9

Thanks very much Hsinvest. I agree with your last line, IF either of their platforms, especially DX1, it will simply be too big and in too great a demand for a small co like Patry's to market. I really believe that the company also sees it that way and won't waste time for the people in need waiting for them to get their marketing act together.
These are too big!!! Brain cancer breast cancer, plus, plus.
Each would HAVE to go to a major pharmaceutical company and there will be strong competition to be that company!!!!
The potential SP as they progress step by step with those platforms i.e. even within that 2 years for clinical trials, is franky indeterminable.
Traders delight in the meantime and we simply have to put up with those nasty reversing fluctuations.
Like it or not, the only ST way of getting rid of that would be for a 1:10 capital consolidation to take it back to where it started @ 50 cents, but, now with a hugely increased state of affairs.